Treatment of relapsed precursor-B acute lymphoblastic leukemia with intensive chemotherapy: POG (Pediatric Oncology Group) study 9411 (SIMAL 9). J Pediatr Hematol Oncol 2013 Oct;35(7):509-13
Date
07/28/2013Pubmed ID
23887024Pubmed Central ID
PMC3957178DOI
10.1097/MPH.0b013e31829f3235Scopus ID
2-s2.0-84885130032 (requires institutional sign-in at Scopus site) 8 CitationsAbstract
Pediatric patients who experience a bone marrow relapse of precursor-B acute lymphoblastic leukemia are cured <50% of the time. This study was designed to determine if intensification of therapies with known activity in this disease would improve the cure rates for patients with relapsed acute lymphoblastic leukemia. Patients were treated with intensive asparaginase during induction followed by repeated cycles of ifosfamide/etoposide and cytarabine/idarubicin. Patients with well-matched related donors were encouraged to undergo hematopoietic stem cell transplant as consolidation. The results of this study demonstrate no significant difference in disease-free survival in patients who received chemotherapy alone (45%) or chemotherapy followed by allogeneic stem cell transplant (50%). Furthermore, results from this study show no significant difference in event-free survival (39.9%±6.2%) or overall survival (41.6%±6.1%) at 8 years when compared with previous studies using less intensive regimens. Our results suggest that alternative therapies are needed to improve cure rates for pediatric patients with relapsed leukemia.
Author List
Kelly ME, Lu X, Devidas M, Camitta B, Abshire T, Bernstein ML, Billett A, Homans A, Sandler E, Buchanan GMESH terms used to index this publication - Major topics in bold
AdolescentAntineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Child
Child, Preschool
Female
Humans
Infant
Male
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Recurrence
Remission Induction
Treatment Outcome